ViroCyt white paper: Exhibitors of the World Vaccine Congress, Washington, 2015

Guest blog: ViroCyt ‘Virotherapy Process Optimization’ white paper

An emerging application of viruses involves engineering them to treat diseases using a number of approaches. Broadly defined under the “Virotherapy” umbrella, these include viral vectors used for gene therapy, oncolytic viruses and viral immunotherapy. A significant challenge, as it is for any virus-based technology, is gaining a clear picture of the quality of a sample at any given point: …

From Cedar and Peanut allergies to Cancer Vaccines and Immunotherapeutics: This is the future of DNA vaccine technology

One company stands on the brink of a revolution in vaccine technology that has the potential to change millions of lives with innovative DNA and RNA vaccines See the future of DNA vaccines: download the report For over 20 years the vaccines industry has pushed towards the goal of creating an effective DNA vaccine. But thus far the industry has …

MaxCyte

Download MaxCyte Flow Electroporation: Vaccine Research & Development

In the run-up to the World Vaccine Congress, MaxCyte has provided us with this whitepaper on Flow Electroporation and its implications in vaccine research and development.  “MaxCyte’s proprietary flow electroporation is a universal transient transfection technology for rapid, high-quality cell transfection. Flow electroporation enables (co)transfection of a wide range of cells with DNA, RNA, siRNA, proteins, or cell lysates and …

White Paper: Scaling-up Influenza: Improving manufacturing agility with GE Healthcare

Overview of a scale-up of a cell-based influenza virus production process using ReadyToProcess equipment posted on behalf of GE Healthcare Life Sciences “The aim of this white paper is to demonstrate how GE Healthcare Life Sciences single-use products can be applied in the field of vaccine manufacturing. The white paper includes a brief discussion around modern vaccine processes, followed by a …

White Paper: Real-Time Baculovirus Quantification With Virus Counter® 2100

Click here to download the White Paper provided by Virocyt on “Real-Time Baculovirus Quantification With Virus Counter® 2100“. Since its first use in the 1980s, the utility of baculovirus to express proteins has grown in both scope and diversity, resulting in approved and clinical-stage drugs and vaccines.  As is the situation with any virus-based product, however, viral quantification is a …

White Paper: Why Virus Quantification Matters

Click here to download the White Paper provided by Virocyt: “Why Virus Quantification matters”. There is growing evidence that the number of non-infectious viral particles is of significant biological importance and can impact both in vitro and in vivo studies. This mounting data suggests a need for rapid quantification of the total number of viral particles in a virus containing …

White Paper provided by Virocyt: An Overview of Virus Quantification Techniques

Click here to download the White Paper provided by Virocyt: “An Overview of Virus Quantification Techniques”. Settings in which viruses play a primary role, such as vaccine production, using viruses to express proteins, the development of antiviral drugs, and therapeutic viruses (oncolytic viruses for example), require accurate assessment of viral concentration across the entire product development lifecycle.  Although time-tested, many …

Download: Replikins whitepaper on preventing influenza pandemics, predicting outbreaks and H5N1

Samuel Bogoch, Chairman of Replikins, kindly provided this whitepaper, ‘The possibility of preventing pandemics: Highest Replikin counts in H5N1 HA and p B1 genes in 2010 and 2011 predict specific new variants with increased infectivity and lethality.’ Download the whitepaper here. The whitepaper argues that, “the possibility of preventing the development of influenza virus outbreaks and pandemics is being considered …

Whitepaper available from LabCorp: sponsor of the World Vaccine Congress Lyon 2012

Labcorp Clinical Trials combines standardized international laboratory capabilities with sophisticated diagnostic technologies to provide a broad portfolio of clinical assays to support drug and diagnostic clinical studies. We have four dedicated central lab facilities located in China, Belgium, Singapore, and the United States. Our scientific team, with expertise across major therapeutic areas, provides extensive support for protocol design and custom …

Download: AfriVax whitepaper on next-gen technologies for egg-based biopharmaceutical manufacturing

Eluemuno Blyden, Founder and CEO of AfriVax, kindly provided this whitepaper entitled, ‘Poultry Pharming: Next-Generation Technologies for Egg-Based Biopharmaceutical Manufacturing.’ Download the whitepaper here. Originally published by IEEE, the whitepaper states that “recombinant vector technologies for embryonated hen eggs are an emerging platform for global health applications including production of vaccines and biologics.” It goes on to suggest that “industrializing …